Evidence map›Paper›PMID 40340822›Full record

ArticleBMC public health2025

Overcoming challenges and achieving high HPV vaccination uptake in Cameroon: lessons learned from a gender-neutral and single-dose program and community engagement.

Andreas Ateke Njoh, Dur-E-Nayab Waheed, Tchokfe Shalom Ndoula Josue Kedakse, Lionel Junior Ebongue, Eugene Justine Kongnyuy, Adidja Amani, Afizu Chrakoh Tambasho, Yauba Saidu, Mohamed Ii Kaba, Clovis Nchinjoh Sangwe and 6 more

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andreas Ateke Njoh *Expanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Dur-E-Nayab Waheed *Centre for Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. nayab.waheed@uantwerpen.be.
Tchokfe Shalom Ndoula Josue KedakseExpanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Lionel Junior EbongueClinton Health Access Initiative Inc, Yaoundé, Cameroon.
Eugene Justine KongnyuySchool of Global Health and Bioethics, Euclid University, Bangui, Central African Republic.
Adidja AmaniFaculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Afizu Chrakoh TambashoExpanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Yauba SaiduClinton Health Access Initiative Inc, Yaoundé, Cameroon.
Mohamed Ii KabaWorld Health Organization, Cameroon Country Office, Yaoundé, Cameroon.
Clovis Nchinjoh SangweDivision of Public Health, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Herman KenfackExpanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Judith SeungueExpanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Daniel NebongoExpanded Program on Immunization, Ministry of Public Health, Yaoundé, Cameroon.
Nadege Edwige NnangGavi, The Vaccine Alliance, Geneva, Switzerland.
Alex VorstersCentre for Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Laurent Cleenewerck de KievSchool of Global Health and Bioethics, Euclid University, Bangui, Central African Republic.

Funding

World Health Organization 001
6 · The paper itself

Abstract

introductionHuman papillomavirus (HPV) is sexually transmissible and affects almost all sexually active people. The virus infects females and males, causing genital warts, cervical cancer, and oropharyngeal cancers in some. The disease burden is highest in resource-constrained countries, and it is a leading cause of cancer-related mortality in Cameroon. HPV infection is preventable by vaccination. Despite the merits of HPV vaccination, improving coverage has remained difficult in Cameroon. This paper highlights the challenges, lessons learned, and progress in HPV vaccination as part of Cameroon's gender-neutral-single-dose approach and the periodic intensification of routine immunization (PIRI).

methodsThis ecological cross-sectional study, conducted from July to December 2023, examines the introduction of the HPV vaccine in Cameroon, along with associated challenges, strategies, and progress. Vaccination data from 2020 to 2023 were retrieved from Cameroon's District Health Information Software (DHIS2), while information on the vaccine introduction process and challenges was sourced from Expanded Programme on Immunisation (EPI) reports. Data analysis was performed using Python. The Shapiro-Wilk test assessed normality, and segmented regression analysis within an interrupted time series framework was applied to evaluate the contribution of each intervention to HPV vaccination uptake among girls. Statistical significance was set at a 95% confidence interval (CI) with a p-value < 0.05. Microsoft Excel 365 was used for calculating vaccination coverage proportions and visualizing results through figures and tables.

resultsCameroon introduced the HPV vaccine to nine-year-old girls in October 2020 amidst negative rumours. The first dose coverage stayed around 20% for three years. Following the National Immunization Technical Advisory Group recommendation, the Ministry of Health intensified communication and community engagement, switched to a single-dose vaccination for nine-year-old boys and girls in January 2023, and PIRI in households and schools in March 2023. All regions improved, with four (Adamawa, East, Far North, and North) having coverages for girls over 90% and around 40% for boys. National-level vaccination coverage for girls improved three-fold, and boys recorded 26%. Interrupted time series highlighted an immediate improvement in girls' vaccination following PIRI in 70% of regions and nationally. In contrast gender-neutral-single-dose vaccination led to immediate improvement in coverage in 30% of regions (Far North, South, South West) and at the national level, while intensified communication lacked significant contribution.

conclusionHPV vaccination in Cameroon has faced significant challenges. However, interventions such as adopting a gender-neutral, single-dose policy and implementing PIRI have greatly improved coverage across various levels of the health system since 2023.

Indexed as

Community ParticipationImmunization ProgramsPapillomavirus InfectionsPapillomavirus VaccinesVaccinationVaccination CoverageAdolescentAdultCameroonChildCross-Sectional StudiesFemaleHumansMaleYoung AdultPapillomavirus VaccinesCameroonCervical cancerGender-neutral vaccinationHPVIntensified communicationPIRISingle-doseVaccination

Identifiers

PMID40340822
PMCPMC12060551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.